HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Accepted manuscript (PDF) All Versions of this Article: JOE-08-0512v1 201/2/169    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Norling, L. Articles by Cooper, D. Search for Related Content PubMed PubMed Citation Articles by Norling, L. Articles by Cooper, D.

L Norling, William Harvey Research Institute, Barts and The London SMD, London, United Kingdom
M Perretti, William Harvey Research Institute, Barts and The London SMD, London, United Kingdom
D Cooper, William Harvey Research Institute, Barts and The London SMD, London, United Kingdom

Correspondence: Mauro Perretti, Email: m.perretti{at}qmul.ac.uk

Abstract

A new era of research is being devoted to decipher endogenous mediators and mechanisms that are in place to resolve the inflammatory response. Accruing evidence indicates that galectins fall into this category of immunoregulatory mediators signifying their use as prospective novel anti-inflammatory agents. The focus of this review is to depict the immunoregulatory bioactivities of three members of the galectin superfamily, Galectin (Gal)-1, Gal-3 and Gal-9. Emphasis is given to the studies investigating the properties of these endogenous lectins. Gal-1, Gal-3 and Gal-9 are emerging as pertinent players in the modulation of acute and chronic inflammatory diseases, autoimmunity and cancer, and thus being increasingly recognised as molecular targets for innovative drug discovery.